A5103148182- Psoriasis: Treatment and Pathogenesis
- T-cell and B-cell Immunology
- Dermatology and Skin Diseases
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Immunodeficiency and Autoimmune Disorders
- Autoimmune Bullous Skin Diseases
- Microbial infections and disease research
- Pharmacological Effects of Natural Compounds
- Cytokine Signaling Pathways and Interactions
- Viral Infectious Diseases and Gene Expression in Insects
- Respiratory viral infections research
- Pediatric health and respiratory diseases
- Urticaria and Related Conditions
- CAR-T cell therapy research
AbbVie (United States)
2013-2021
AbbVie (Japan)
2013
Massachusetts Academy of Math and Science
2013
University of Illinois Chicago
1994
Abstract IL-36 cytokines are pro-inflammatory members of the IL-1 family that upregulated in inflammatory disorders. Specifically, IL-36γ is highly expressed active psoriatic lesions and can drive processes 3D human skin equivalents supporting a role for this target inflammation. Small molecule antagonists interleukins have been historically challenging to generate. Nevertheless, we performed small high-throughput screen identify using novel TR-FRET binding assay. Several compounds,...
Signal transduction through the interleukin-1 receptor (IL-1R) pathway mediates a strong pro-inflammatory response, which contributes to number of human diseases such as rheumatoid arthritis. Within IL-1 family, IL-1α and IL-1β are both agonistic ligands for IL-1R, whereas antagonist (IL-1ra) is an endogenous that binds IL-R, but does not signal. Therefore, ideal therapeutic strategy would be blocking IL-1β, IL-1ra. However, due low sequence homology between three members it has been...
IL-36 cytokines signal through the receptor (IL-36R) and a shared subunit, IL-1RAcP (IL-1 accessory protein). The activation mechanism for pathway is proposed to be similar that of IL-1 in an IL-36R agonist (IL-36α, IL-36β, or IL-36γ) forms binary complex with IL-36R, which then recruits IL-1RAcP. Recent studies have shown interacts even absence agonist. To elucidate mechanism, we considered all possible binding events ligands/receptors examined these direct assays. Our results indicated...
Abstract CTLA4-Ig/abatacept dampens activation of naive T cells by blocking costimulation via CD28. It is an approved drug for rheumatoid arthritis but failed to deliver efficacy in a number other autoimmune diseases. One explanation that activated rely less on CD28 signaling and use alternate coreceptors effector function. ICOS critical T-dependent humoral immune responses, which drives pathophysiology IgG-mediated In this study, we asked whether play nonredundant roles maintenance...
Efficient production of large quantities therapeutic antibodies is becoming a major goal the pharmaceutical industry. We developed proprietary expression system using polyprotein precursor-based approach to antibody in mammalian cells. In this approach, coding regions for heavy and light chains are included within single open reading frame (sORF) separated by an in-frame intein gene. A mRNA subsequent polypeptide produced upon transient stable transfection into HEK293 CHO cells,...